Human immunodeficiency virus reverse transcriptase and protease sequence database

Nucleic Acids Research

Volumn 31, Issue 1, 2003, Pages 298-303

  Rhee, Soo Yoon ^a   Gonzales, Matthew J ^a   Kantor, Rami ^a   Betts, Bradley J ^a   Ravela, Jaideep ^a   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN GP 41; INTEGRASE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; CELL FUSION; CLINICAL STUDY; GENBANK; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFORMATION PROCESSING; MEDLINE; NONHUMAN; ONLINE SYSTEM; PRIORITY JOURNAL; PROTEIN TARGETING; PUBLICATION; REVIEW; SEQUENCE DATABASE; VIRUS ISOLATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DATABASES, PROTEIN; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PHENOTYPE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0037250521     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkg100     Document Type: Review

References (13)

1. Shafer,R.W. (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev., 15, 247-277.
2. Hirsch,M.S., Brun-Vezinet,F., D'Aquila,R.T., Hammer,S.M., Johnson,V.A., Kuritzkes,D.R., Loveday,C., Mellors,J.W., Clotet,B., Conway,B. et al. (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA, 283, 2417-2426.
3. Kantor,R., Machekano,R., Gonzales,M.J., Dupnik,B.S., Schapiro,J.M. and Shafer,R.W. (2001) Human immunodeficiency virus reverse transcriptase and protease sequence database: An expanded model integrating natural language text and sequence analysis. Nucleic Acids Res., 29, 296-299.
4. Shafer,R.W., Jung,D.R. and Betts,B.J. (2000) Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nature Med., 6, 1290-1292.
5. Kilby,J.M., Hopkins,S., Venetta,T.M., DiMassimo,B., Cloud,G.A., Lee,J.Y., Alldredge,L., Hunter,E., Lambert,D., Bolognesi,D. et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med., 4, 1302-1307.
6. Kilby,J.M., Lalezari,J.P., Eron,J.J., Carlson,M., Cohen,C., Arduino,R.C., Goodgame,J.C., Gallant,J.E., Volberding,P., Murphy,R.L. et al. (2002) The Safety, Plasma Pharmacokinetic, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Medicated Virus Fusion, in HIV-Infected Adults. AIDS Res. Hum. Retroviruses, 18, 685-693.
7. Wei,X., Decker,J.M., Liu,H., Zhang,Z., Arani,R.B., Kilby,J.M., Saag,M.S., Wu,X., Shaw,G.M. and Kappes,J.C. (2002) Emergence of resistant hyman immunodeciency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother., 46, 1896-1905.
8. Sista,P.R., Melby,T., Greenberg,M., Davison,D., Jin,L., Mosier,S., Mink,M., Nelson,E., Fang,L., Cammack,N. et al. (2002) Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antivir. Ther., 7, S16-S17.
9. Grobler,J.A., Stillmock,K., Hu,B., Witmer,M., Felock,P., Espeseth,A.S., Wolfe,A., Egbertson,M., Bourgeois,M., Melamed,J. et al. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA, 99, 6661-6666.
10. Hazuda,D.J. and HIV-1 Integrase Inhibitor Discovery Team (2002) A novel HIV-1 integrase inhibitor mediates sustained suppression of viral replication and CD4 depletion in a SHIV rhesus macaque model of infection. Antivir. Ther., 7, S3.
11. Hertogs,K., de Bethune,M.P., Miller,V., Ivens,T., Schel,P., Van Cauwenberge,A., Van Den Eynde,C., Van Gerwen,V., Azijn,H., Van Houtte,M. et al. (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency veirus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother., 42, 269-276.
12. Petropoulos,C.J., Parkin,N.T., Limoli,K.L., Lie,Y.S., Wrin,T., Huang,W., Tian,H., Smith,D., Winslow,G.A., Capon,D.J. et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 44, 920-928.
13. Beerenwinkel,N., Schmidt,B., Walter,H., Kaiser,R., Lengauer,T., Hoffmann,D., Korn,K. and Selbig,J. (2002) Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc. Natl Acad. Sci. USA, 99, 8271-8276.